Evidence-based hyperbaric oxygen therapy research, chamber comparisons, treatment protocols, and condition-specific guides built for clinicians, researchers, and informed patients.
Browse by chamber type, clinical indication, or treatment protocol
Monoplace, multiplace, hard-shell, soft-shell, and portable chambers — specifications, use cases, and typical costs.
Evidence-based HBOT research for neurological, wound, and other indications — from UHMS-approved to experimental.
Standard HBOT treatment protocols by pressure (1.3 ATA mild to 3.0 ATA clinical) and by clinical indication.
HBOT research for traumatic brain injury, stroke, long COVID, and persistent post-concussion syndrome.
UHMS-approved HBOT indications: diabetic ulcers, radiation injury, burns, crush injury, and compromised grafts.
Clinical trial breakdowns, HBOT news, and in-depth guides on hyperbaric medicine from the HBOT Hub research desk.
From chamber selection and indication review to pressure-level protocols and the regulatory landscape — HBOT Hub covers the full picture.
Monoplace, multiplace, hard-shell, soft-shell, and portable chambers — specifications, pressure ranges, use cases, and typical costs for every clinical and home-use configuration.
Compare Chambers →Research-based summaries for 20+ HBOT indications: UHMS-approved conditions, neurological applications (TBI, stroke, long COVID), and experimental research-stage uses.
Browse Conditions →Standard HBOT protocols by pressure (1.3 ATA mild through 2.8 ATA emergency) and by indication — session length, course length, and evidence base for each.
View Protocols →UHMS-approved indications, FDA chamber clearances, CMS reimbursement, and the clinical safety framework — contraindications, barotrauma, oxygen toxicity.
Open Guidance →"Finally an HBOT reference that doesn't read like a sales page. The chamber comparisons and condition write-ups actually cite the Efrati-lab literature."
"The protocol pages are the clearest 1.3 vs 2.0 vs 2.4 ATA breakdown I've found anywhere. I link patients here before their first consult."
"I use the monoplace vs multiplace page as a patient handout. Clear, balanced, and properly caveated. Exactly what we need in this space."
"The condition evidence tiers are what set this site apart — UHMS-approved separated from research-stage, with the trial citations spelled out."
"The long COVID and TBI pages are the best plain-language summaries I've seen outside a specialist textbook. Great starting point for new patients."
"Clean design, fast loading, and the regulatory section accurately reflects UHMS and CMS. Hard to find that level of accuracy in HBOT content."
"As someone new to referring patients for HBOT, the FAQ and safety guidelines gave me a solid foundation before I looked at specific protocols."
"Bookmark-worthy. The 2.0 ATA neurological protocol breakdown is exactly what I needed to understand the Efrati lab approach."
Curated educational content for clinicians and researchers
Peer-reviewed HBOT research across UHMS-approved and research-stage indications — organised by evidence tier.
Browse Research →Contraindications, pre-treatment screening, barotrauma prevention, and in-chamber safety discipline.
View Guidelines →Common questions about HBOT: chambers, pressure levels, treatment courses, UHMS indications, safety, and cost.
Read FAQ →UHMS-approved indications, FDA chamber clearances, and CMS reimbursement criteria for US HBOT facilities.
Read Guidance →In-depth guides and analysis from our research team
The first randomised controlled trial of hyperbaric oxygen therapy for long COVID demonstrated significant improvement in cognitive, physical, and quality-of-life measures after 40 sessions at 2.0 ATA.
Monoplace and multiplace chambers deliver equivalent HBOT at the pressure level, but differ substantially in logistics, cost, patient experience, and clinical workflow.
Soft-shell "mild HBOT" at 1.3 ATA is marketed widely for wellness and recovery. The clinical evidence is thinner than most promotional material suggests.
The information provided on HBOT Hub is for educational and research purposes only. It is not intended as medical advice, diagnosis, or treatment. HBOT is a prescription medical treatment and may not be approved for human use by the FDA or equivalent regulatory bodies. Always consult a qualified healthcare professional before considering any HBOT protocol.
Read Full Disclaimer →